Indigo Diabetes’ continuous multi-metabolite monitoring (CMM) sensor is a small spectrometer-on-a-chip to monitor multiple metabolites in-vivo simultaneously and continuously.
The inert, miniature integrated silicon photonics spectrometer chip measures the absorption of light in the interstitial fluid to quantify the concentration of multiple metabolites simultaneously without the use of enzymes or fluorophores.
Once inserted under the skin, the CMM sensor is invisible to the naked eye and will connect securely and wirelessly to mobile devices via Bluetooth to share the concentration profiles of the user’s metabolites with their caregivers and family members. A rechargeable sensor battery powers the measurements.
It is expected that the sensor will have a lifetime of up to two years. Preclinical studies have successfully demonstrated proof of concept with promising accuracy.
Indigo uses ground-breaking nanophotonics technology to analyse levels of metabolites via an on-chip miniature spectrometer. The inert, miniature spectrometer chip measures the absorption of light in the individual’s interstitial fluid to quantify the concentration of multiple metabolites simultaneously without the use of enzymes or fluorophores.
Indigo’s CMM sensor is protected by more than a dozen international patent families.
Indigo has received ISO 13485 certification from TÜV Süd for the Design and Development of Biomarker Sensing Devices and Services.
Other Future Applications
There are many potential uses for our CMM sensor. We are exploring applications beyond diabetes management to light up the life of many people.